MedTrace Logo

Comparing the Gastric Transit of Commercial Milk and A2 Milk

NCT05658861 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-11-21

No results posted yet for this study

Summary

Cow's milk contains two types of β-casein: A1 and A2. The μ-opioid peptide BCM-7 is released from A1 but not from A2. BCM-7 is associated with slower gastrointestinal transit and hence increased gastrointestinal transit times. Lactose maldigesters reported an increase in abdominal pain due to consumption of milk containing A1 beta-casein as compared to milk containing only A2 beta-casein. The hypothesis of this study is that the differential abdominal pain is due to the differential gastric transit. This is a double-blinded, randomized, controlled trial conducted to determine if the transit of A1 β-casein milk is modified in the stomach as compared to milk with only A2 β-casein.

Conditions

  • Lactose Intolerance, Adult Type

Interventions

OTHER

Milk containing A1 and A2 beta-casein

Single dose of commercial milk

OTHER

Milk containing only A2 beta-casein

Single dose of A2 milk

Sponsors & Collaborators

  • Purdue University

    lead OTHER

Principal Investigators

  • Dennis Savaiano, PhD · Purdue University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-21
Primary Completion
2022-10-06
Completion
2022-12-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05658861 on ClinicalTrials.gov